David W. Dodick

Overview

Best Publications

• A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

  Brian G. Weinshenker;Peter C. O'Brien;Tanya M. Petterson;John H. Noseworthy

  1127
  Citations

• New Appendix Criteria Open for a Broader Concept of Chronic Migraine

  J. Olesen;M -G Bousser;H -C Diener;D. Dodick

  1096
  Citations

• OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program

  David W. Dodick;Catherine C. Turkel;Ronald E. Degryse;Sheena K. Aurora

  1090
  Citations

• Narrative review: reversible cerebral vasoconstriction syndromes.

  Leonard H. Calabrese;David W. Dodick;Todd J. Schwedt;Aneesh B. Singhal

  1056
  Citations

• Fremanezumab for the Preventive Treatment of Chronic Migraine

  Stephen D. Silberstein;David W. Dodick;Marcelo E. Bigal;Paul P. Yeung

  862
  Citations

• Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial

  Tony W Ho;Michel D Ferrari;David W Dodick;Vince Galet

  762
  Citations

• A self-administered screener for migraine in primary care: The ID Migraine™ validation study

  Richard B. Lipton;D. Dodick;R. Sadovsky;K. Kolodner

  751
  Citations

• Migraine

  Unknown

  615
  Citations

• Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

  Stephen D. Silberstein;Richard B. Lipton;David W. Dodick;Frederick G. Freitag

  602
  Citations

• ARISE: A Phase 3 randomized trial of erenumab for episodic migraine:

  David W Dodick;Messoud Ashina;Jan Lewis Brandes;David Kudrow

  600
  Citations

• Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial

  Richard B Lipton;David W Dodick;Stephen D Silberstein;Joel R Saper

  543
  Citations

• A Phase‐by‐Phase Review of Migraine Pathophysiology

  David W. Dodick

  496
  Citations

• Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

  David W Dodick;Peter J Goadsby;Peter J Goadsby;Stephen D Silberstein;Richard B Lipton

  488
  Citations

• Adherence to oral migraine-preventive medications among patients with chronic migraine:

  Zsolt Hepp;David W Dodick;Sepideh F Varon;Patrick Gillard

  475
  Citations

• Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Long-term results from a randomized, multicenter, double-blinded, controlled study

  David W. Dodick;Stephen D. Silberstein;Kenneth L. Reed;Timothy R. Deer

  433
  Citations

• Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial

  Hong Sun;David William Dodick;Stephen Silberstein;Peter J. Goadsby

  407
  Citations

• Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

  Cristina Tassorelli;Hans-Christoph Diener;David W Dodick;Stephen D Silberstein

  388
  Citations

• Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

  Marcelo E Bigal;David W Dodick;Alan M Rapoport;Stephen D Silberstein

  374
  Citations

• Ubrogepant for the Treatment of Migraine.

  David W. Dodick;Richard B. Lipton;Jessica Ailani;Kaifeng Lu

  373
  Citations

• Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT1B/1D Agonists) in the Acute Treatment of Migraine

  David Dodick;Richard B. Lipton;Vincent Martin;Vasilios Papademetriou

  335
  Citations

• A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine:

  Tiffini Voss;Richard B Lipton;David W Dodick;Nicole Dupre

  273
  Citations

• Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.

  Richard B. Lipton;David W. Dodick;Jessica Ailani;Kaifeng Lu

  252
  Citations

• OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.

  Stephen D. Silberstein;Andrew M. Blumenfeld;Roger K. Cady;Ira M. Turner

  248
  Citations